Aclarion, Inc. Common Stock (ACON) is a publicly traded Healthcare sector company. As of May 21, 2026, ACON trades at $3.14 with a market cap of $7.88M and a P/E ratio of -0.36. ACON moved +2.19% today. Year to date, ACON is -38.42%; over the trailing twelve months it is -54.10%. Its 52-week range spans $2.34 to $3,499.51. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces ACON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aclarion Logs 196% Scan Volume Surge, CEO Buys Shares and Unveils $2.5M Buyback: Aclarion reported a 196% year-over-year increase in Q1 2026 Nociscan platform scans, signaling strong adoption of its AI chronic back pain solution. CEO Ness Brent purchased 6,289 shares, raising his stake to 6,300 shares, as the company maintains no debt, funds operations into 2027 and launches a $2.5 million buyback.
| Metric | Value |
|---|---|
| Price | $3.14 |
| Market Cap | $7.88M |
| P/E Ratio | -0.36 |
| EPS | $-9.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $3,499.51 |
| 52-Week Low | $2.34 |
| Volume | 15 |
| Avg Volume | 0 |
| Revenue (TTM) | $77.88K |
| Net Income | $-8.05M |
| Gross Margin | 19.35% |
1 analysts cover ACON: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.